Over 40 million Americans have been prescribed a GLP-1 medication. Most of them were never told the five things in this report. That gap between what the prescriber says and what the science shows is costing people their muscle mass, their metabolism, and their long-term results.

The GLP-1 revolution is real. Semaglutide and tirzepatide have fundamentally changed weight management—producing 15–22% total body weight loss in clinical trials, reducing cardiovascular events by 20%, and earning recognition from the World Health Organization as a cornerstone of chronic obesity treatment.

But here is what the $38-billion-a-year GLP-1 industry does not want on the front page: the medication alone is a half-measure. Without a clinical protocol built around it, patients lose muscle, regain weight, and develop nutritional deficiencies that undermine the very health outcomes they were chasing.

This report is the corrective. No sales pitch. No hype. Just what the evidence says, what the guidelines recommend, and what a physician-led approach actually looks like.

I. The 5 Things Nobody Told You About GLP-1s

01

You're Losing Muscle, Not Just Fat

The number on the scale is going down. That feels like progress. But clinical data tells a different story: 25–40% of the weight you lose on a GLP-1 is lean muscle mass, not fat. This is the "skinny fat" problem that telehealth startups ignore because it doesn't fit a marketing slide.

Muscle is metabolically active tissue. Lose it, and your resting metabolic rate drops. Your body burns fewer calories at rest. When you eventually stop the medication—and most people do—you regain weight faster because your engine is smaller.

25–40%
of weight lost on GLP-1s is lean muscle mass, not adipose tissue. The STEP 1 trial documented significant lean mass reduction alongside fat loss.
Source: Wilding et al., NEJM 2021; Sargeant et al., Obesity Reviews 2024
02

Weight Regain Is the Norm, Not the Exception

Industry marketing implies the weight stays off. The data says otherwise. A meta-analysis of GLP-1 discontinuation studies found patients regain an average of 0.8 kg per month after stopping, returning to near-baseline weight within approximately 1.7 years.

This is not a failure of willpower. It is a predictable biological response: GLP-1 medications suppress appetite centrally. Remove the signal, the appetite returns. Without a structured maintenance protocol—behavioral, nutritional, and pharmacological—regression is the default outcome.

~1.7y
Average time to return to baseline weight after GLP-1 discontinuation without a structured maintenance protocol.
Source: Wilding et al., JAMA 2024; Rubino et al., STEP 4 Extension
Person stepping on a scale tracking their weight loss progress
Tracking progress goes beyond the scale. Body composition matters more than the number.
03

Your Nutritional Foundation Is Eroding

GLP-1 medications reduce appetite dramatically—that is the point. But when caloric intake drops 30–40%, so does micronutrient intake. Over 90% of GLP-1 patients are deficient in at least one critical micronutrient: Vitamin D, potassium, magnesium, and B12 are the most common gaps.

🔒

Continue Reading:
The Full Investigation

You have read what the industry hides. Enter your email to unlock the complete investigation—supplement protocols, the FDA crackdown, what the science says works, and what to actually do about it.

No spam. No sales calls. Unsubscribe anytime.

Only 20% of patients prescribed GLP-1s receive a referral to a registered dietitian. The rest are left to navigate severe appetite suppression without guidance, developing deficiencies that manifest as fatigue, hair loss, bone density reduction, and cognitive fog.

Clinical Warning

GLP-1-induced appetite suppression can mask malnutrition. Baseline labs (Vitamin D, B12, ferritin, comprehensive metabolic panel) should be drawn before initiation and monitored quarterly. Bone density screening is recommended for patients over 50 or those with greater than 15% body weight loss.

04

The FDA Is Cracking Down—and Your Provider Might Be Next

In March 2026, the FDA issued 30 warning letters in a single action to telehealth companies illegally marketing compounded GLP-1 medications. This was more enforcement activity than the prior decade combined.

The compounding loophole that allowed cheaper alternatives during the semaglutide shortage has closed. FDA declared shortages resolved. Companies still selling compounded semaglutide and tirzepatide are operating outside FDA guidance—and patients are the ones bearing the safety risk.

05

A Prescription Alone Is Not a Protocol

The WHO's December 2025 landmark classification of obesity as a chronic disease explicitly requires long-term pharmacological therapy combined with intensive behavioral intervention. A 5-minute video call and a recurring prescription does not meet that standard.

The telehealth companies that scaled fastest did so by removing friction—including the clinical friction that exists to protect you. No lab work. No follow-up. No dietary protocol. No resistance training guidance. No monitoring of the muscle loss happening beneath the weight loss.

Physician's Note

We see it weekly: patients who have been on semaglutide for six months through an online provider, lost 40+ pounds, and have never had a single lab drawn or a conversation about protein intake. They feel great because they are lighter. But their metabolic health is often worse than when they started. That is not weight loss—that is metabolic borrowing.

Doctor consulting with patient in a modern medical office
Physician-led care means real consultations, real labs, and real follow-up—not a chatbot.

II. What the Science Actually Says Works

The clinical evidence is clear: GLP-1 medications produce the best outcomes when embedded in a comprehensive protocol. Not as a standalone prescription. Here is what the literature supports:

The Protein Imperative

Patients on GLP-1 therapy require 1.2–2.0 grams of protein per kilogram of body weight per day to preserve lean muscle mass. For a 180-pound person, that is 98–164 grams daily. Most patients on GLP-1s, with their heavily suppressed appetite, are getting less than half that.

Colorful healthy meal with fresh vegetables and quinoa
High-protein, nutrient-dense meals are the foundation of any GLP-1 protocol.

Resistance Training: Non-Negotiable

Two to three sessions per week of progressive resistance training is the single most effective intervention for mitigating GLP-1-induced muscle loss. Cardio alone does not solve this.

The Evidence-Based Supplement Stack

SupplementDosePurposePriority
Whey/Plant Protein30–50g/dayMuscle preservation, satietyCritical
Creatine Monohydrate5g/dayLean mass retention, strengthCritical
HMB3g/dayAnti-catabolic, muscle sparingImportant
Vitamin D32,000–5,000 IU/dayBone health, immune functionCritical
Magnesium Glycinate400mg/dayMetabolic function, sleepImportant
Fiber Supplement10–15g/dayGI regularity (GLP-1 side effects)Recommended
Vitamin B121,000mcg/dayEnergy, neurological functionImportant
Omega-3 (EPA/DHA)2–3g/dayInflammation, cardiovascularRecommended
Supplement capsules arranged on a table with morning routine
The right supplement protocol is standard of care, not an upsell.
Physician's Note

Every patient we start on a GLP-1 gets this stack from day one. Not as an upsell—as standard of care. The creatine alone has more evidence behind it than most things in medicine. Five grams a day. Cheap. Safe. Non-negotiable for anyone losing weight rapidly.

III. The 2026 GLP-1 Landscape: What Changed

Pricing Collapsed

Novo Nordisk announced up to 50% cuts on Wegovy and Ozempic list prices. Medicare negotiated $274/month under the Inflation Reduction Act. Cash-pay programs now range $149–$499/month.

Tirzepatide Emerged as Superior

The SURMOUNT trials established tirzepatide (Mounjaro/Zepbound) as the most effective weight-loss medication available, producing approximately 20% body weight reduction versus 14% for semaglutide.

The Cardiovascular Signal Is Real

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in patients on semaglutide. This moved GLP-1s from "weight loss drugs" to "cardiometabolic medications."

20%
Reduction in major cardiovascular events (MACE) demonstrated in the SELECT trial, independent of weight loss.
Source: Lincoff et al., SELECT Trial, NEJM 2023

IV. How to Actually Do This Right

Before You Start

☑ Comprehensive metabolic panel + baseline labs
☑ Body composition analysis (DEXA scan preferred)
☑ Honest assessment of protein intake, exercise habits, and sleep
☑ Cardiovascular risk evaluation
☑ Clear discussion of realistic timelines and maintenance planning

During Treatment

☑ Protein: 1.2–2.0g per kg body weight, every day
☑ Resistance training: 2–3 sessions per week
☑ Supplement protocol (see table above)
☑ Monthly physician follow-up
☑ Quarterly labs: metabolic panel, vitamin levels, body composition
☑ Hydration: minimum 80oz water daily

Active healthy person jogging outdoors on a sunny day
The goal is not just weight loss. It is building a life you can sustain.

The Exit Strategy Nobody Talks About

Every patient should have a discontinuation plan from month one. Whether you taper to a maintenance dose or transition off entirely, the protocol for keeping results is different from the protocol for getting them.

Ready for a Program That Gets This Right?

Everything in this report—the labs, the protein protocols, the supplement stack, the exit strategy—is exactly what Teleios Health delivers. Physician-led. Evidence-based. Starting at $99/month.

Start Your Physician-Led Program →
Teleios Health · Board-certified physicians · Nationwide · Lab-monitored protocols

V. What Sets Physician-Led Care Apart

ComponentOnline Rx MillPhysician-Led Protocol
Initial Assessment5-min questionnaireFull labs + body composition + history
ProviderRotating NPs or PAsBoard-certified physician continuity
Lab MonitoringNone or annualQuarterly comprehensive panels
Muscle PreservationNot addressedProtein + creatine + resistance Rx
Nutrition GuidanceGeneric PDFIndividualized macro targets + RD access
Discontinuation PlanNoneTapering + maintenance protocol from day 1
Follow-upAutomated refillMonthly physician check-in
From the Medical Review Board

Weight loss is not the goal. Metabolic health is the goal. Weight loss is a byproduct. When we see a patient who has lost 50 pounds but their lean mass has dropped 20%, their vitamin D is in the basement, and they have never touched a weight—that is not a success story. That is a ticking clock. The standard of care must be higher. Programs like Teleios Health exist precisely because this gap needed closing.